Table
3: Outcomes
among diabetic patients followed at baseline and 6, 12, 18 and 24 months.
|
|
Baseline |
6 months |
12 months |
18 months |
24 months |
||||||
|
Number
of patients with enough time between enrollment and study end to be included |
544 |
517 |
478 |
423 |
394 |
||||||
|
Alive
and in care, by end of milestone (n, %) |
544 |
100% |
475 |
91.9% |
415 |
86.8% |
357 |
84.4% |
316 |
80.2% |
|
|
If Alive, No. with HbA1c tested |
70 |
29 |
57 |
64 |
64 |
||||||
|
Median HbA1c |
10.3 (8.3-11.9) |
8.5 (6.0-11.0) |
8.2 (6.1-10.2) |
8.4 (6.7-9.6) |
8.6 (6.5-10.2) |
||||||
|
If Alive, No. with HbA1c tested and baseline HbA1c ≥ 10 |
38 |
4 |
9 |
5 |
2 |
||||||
|
Median HbA1c |
12.0 (11.2-13.0) |
8.2 (6.0-10.4) |
8.1 (5.9-11.0) |
9.3 (9.1-10.1) |
7.7 (6.9-8.5) |
||||||
|
Died,
by end of milestone (out of those with sufficient follow up) (n, %) |
N/A |
5 |
1.0% |
8 |
1.7% |
14 |
3.3% |
12 |
3.0% |
||
|
Lost
to follow up, by end of milestone (n, %) |
N/A |
37 |
7.2% |
55 |
11.5% |
52 |
12.3% |
66 |
16.8% |
||
‡Hba1c measured in the following
windows: baseline: 0-3 months; 6 months: 4-6 months; 12 months: 7-12 months; 18
months: 13-18 months; 24 months: 19-24 months